AbCellera Biologics Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Full Time Employees
- 596
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2215 Yukon Street Vancouver BC Canada V5Y 0A1
- IPO Date
- Dec 11, 2020
- CIK
- 0001703057
- Website
- abcellera.com
- Similar Companies
- Business
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Company News
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
AbCellera Reports Full Year 2024 Business Results
AbCellera to Participate at Upcoming Investor Conferences in March
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
AbCellera Biologics: Still A Concept Stock
AbCellera to Present at Upcoming Investor Conferences in December and January
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates
AbCellera to Present at Upcoming Investor Conferences in November 2024
AbCellera: A Platform To Pipeline Transition
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
AbCellera: A Waiting Game With High Uncertainty
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?